Biweekly analysis of the US healthcare advertising market — covering July 9 to 23, 2026.
Two weeks were enough to rewrite the rules of the game. A lawsuit between the two largest GLP-1 manufacturers put comparative advertising on trial. Medicare began covering obesity medications for the first time in history, opening a market of millions of patients over 65. And the first commercial activation of a technology that connects physician prescribing data to consumer campaign targeting went live.
We monitor the US trade press and select the signals that genuinely matter to the people who produce, approve, and run pharmaceutical communications. Below are the seven moves of the period — and what each one demands from marketing teams.
1. Novo Nordisk sues Eli Lilly over misleading advertising
On July 21, Novo Nordisk filed suit in federal court in New Jersey accusing Eli Lilly of running a "nationwide pattern of misleading advertising." The core allegation: Lilly compares the highest doses of Zepbound and Mounjaro against lower — and already outdated — doses of Wegovy and Ozempic, omitting the new 7.2 mg dose approved by the FDA in March.
Novo is seeking a permanent injunction to pull the creative and is demanding that Lilly run a corrective advertising campaign. The complaint cites violations of the Lanham Act and state unfair competition laws, and follows an out-of-court notice in April that Lilly did not act on. Lilly responded that its advertising is "truthful, transparent, and grounded in the most direct scientific evidence available."
Why it matters: the challenged creative ran during World Cup broadcasts and on TikTok and Facebook. This is the first litigation between two major pharma companies specifically over DTC advertising — and it sets precedent for every comparative claim in the industry. If you work with promotional material, claim validation just got more expensive.
Sources: BioPharma Dive · STAT News · CNBC · Forbes · Bloomberg · NBC News
2. Medicare covers obesity for the first time — creating an entirely new audience
On July 1, the Medicare GLP-1 Bridge went live: a CMS demonstration that provides access to Wegovy (injectable and pill), Zepbound (KwikPen formulation), and Foundayo for US$ 50 per month. The program runs through December 31, 2027 and operates outside the traditional Part D flow — plans do not carry the risk.
Federal law prohibits Medicare from covering weight-loss drugs; CMS worked around the restriction using its authority to run demonstration projects. Eligibility combines a BMI of 27 or higher with a comorbidity (prediabetes, uncontrolled hypertension, cardiovascular disease). Estimates from Novo and Lilly point to 15 to 20 million Medicare adults who would qualify.
Why it matters: a 65+ patient segment that has never been targeted by obesity campaigns appears overnight. Messaging, channels, tone of voice, and support materials all need to be rethought for an audience whose digital literacy, comorbidities, and decision journey differ completely from the 35–55 audience that has dominated the category so far.
Sources: CMS — Medicare GLP-1 Bridge · CMS — Information for Part D plans · Medicare.gov · CNBC · CNN · NPR · Medicare Rights Center
3. The HCP↔DTC silo has started to fall for real
On July 23, PulsePoint and CMI Media Group announced the first commercial agency activation of HCP2DTC Influence™ — technology that uses physician prescribing propensity signals to model and optimize targeting for consumer-directed campaigns, in real time and within a unified programmatic strategy.
The logic: instead of building DTC audiences in a vacuum, the demand generated by the consumer campaign arrives at the moment the physician is most likely to prescribe. Andrew Stark, Chief Commercial Officer at PulsePoint, described the disconnect between HCP and DTC programs as "one of the most persistent blind spots in pharma media." CMI Media Group, part of WPP, is the first agency to put the solution into production.
Why it matters: the industry has been talking about omnichannel for years, but execution stayed separate — different teams, different KPIs, different platforms. This is the first commercial product that attacks the problem at the infrastructure level. Anyone running technical production and campaign automation needs to prepare for synchronized orchestration across both fronts, not merely parallel ones.
Sources: PR Newswire — HCP2DTC Influence™ launch · PR Newswire — first agency activation · PulsePoint — Pharma Forward 2026 · Solli
4. World Cup: the media lesson pharma learned in practice
Six health brands advertised during the tournament. Haleon led pharmaceutical airings on English-language broadcasts, according to iSpot.TV data published by Fierce Pharma. But the more revealing data point is another: there was a genuine shortage of pharma inventory in the matches — few breaks available in live broadcasts, and most of them reserved for official sponsors.
In June's ad spending ranking, Tremfya (J&J) took the lead back from Skyrizi (AbbVie), which fell from US$ 38.9 million in May to US$ 23.3 million. Zepbound (Lilly) came in fourth. The technical recommendation that emerged from the period: treat live events as a contextual awareness buy and concentrate effort on programmatic-first — CTV, streaming, online video, DOOH, and sports-adjacent content.
Worth noting the branding critique raised by the Kantar/MM+M analysis in the previous sports-event cycle: celebrity and emotional narrative are no substitute for clarity. The brand's role needs to appear explicitly and early in the creative.
Sources: Fierce Pharma — ad spending ranking and the World Cup · MM+M — 6 health brands at the World Cup · Campaign US · DeepIntent — programmatic guide for the World Cup · MM+M — lessons from the Winter Games · Unlock Health · Pharmaceutical Reform Alliance
5. Agentic AI left the talking stage and became a commercial category
The movement is no longer conceptual. Converteo launched an international agentic AI offering dedicated to Pharma & Life Sciences. Ogury introduced SONA, an agentic solution to close the gap between audience planning and campaign execution. And Doceree hired leaders from TripleLift and IPG Mediabrands into the Chief AI Officer and Chief Innovation Officer seats.
The technical consensus that has formed is more interesting than the hype. The value of AI in pharma marketing lies in the workflow, not in loose content generation. Where it works: audience design and segmentation, real-time bid optimization, modular reuse of already-approved assets, MLR process support, localization, and field force enablement. Where it fails: uncontrolled generated copy that alters fair balance and comes back rejected by MLR — costing more time than it saved.
The numbers behind the shift
- US$ 26.2 billion is the projected digital investment in pharmaceutical advertising in 2026, against US$ 6.9 billion in traditional channels.
- 82% of all pharma/healthcare media spend is expected to be digital by 2027, with linear TV falling to a 12% share.
- 64% of marketers in the sector point to fragmentation across platforms and publishers as their main challenge; 55% cite AI governance and brand safety.
- 37% of US consumers already use generative AI to research health topics — and those searches do not necessarily lead to the brand's website.
- 100% of respondents consider orchestration across adtech systems important; 60% rate it as extremely important.
Sources: Innovid — 2026 Pharmaceutical & Healthcare Advertising Outlook · PulsePoint — 2026 Health Marketing Trends Report · DeepIntent — 2026 trends · DeepIntent — agentic AI at AdLab 2026 · Solli — AI inflection point · Spectrum Science — 2026 predictions
6. Celebrity + disease awareness: the playbook is now settled
ARS Pharmaceuticals put Drew Brees — Super Bowl champion and NFL Hall of Fame class of 2026 — at the center of a severe allergy awareness campaign tied to Neffy, an epinephrine nasal spray. Brees lives with a food allergy, and the creative axis is preparedness and routine, not the product. In the same period, Lilly activated Shaquille O'Neal in a national campaign about obstructive sleep apnea, anchored in Zepbound's expanded indication.
The pattern: an expanded indication becomes an awareness campaign, and the celebrity delivers reach plus lived-experience legitimacy. Type I reactions affect roughly 40 million people in the US, 33 million of whom have a food allergy — a scale that justifies mass media investment.
Sources: Fierce Pharma · MM+M (podcast with Drew Brees) · Allergic Living
7. Therapeutic psychedelics: the next frontier with no playbook
On July 14, the FDA published in the Federal Register the final version of its guidance Psychedelic Drugs: Considerations for Clinical Investigations, addressing the functional unblinding problem that sank Lykos's MDMA application in 2024. In the same document, the agency announced a public hearing for September 14, 2026 — a signal that it is building the institutional infrastructure for a real approval pipeline.
The context: in April, an executive order called for accelerated research and review of psychedelics for serious mental health disorders, and the FDA issued National Priority Vouchers to Compass Pathways (psilocybin for treatment-resistant depression), Usona Institute (psilocybin for major depression), and Transcend Therapeutics (methylone for PTSD) — vouchers that compress review from 10–12 months to 1–2 months. Compass is targeting an NDA submission in Q4 2026.
Why it matters: there is already an active LSD brand campaign aimed at therapists. This is an entire therapeutic category heading to market with no DTC marketing precedent — no creative playbook, no regulatory case law, no MLR benchmark. Whoever builds that framework first sets the standard.
Sources: Federal Register — guidance and public hearing · TechTimes · Morgan Lewis · Psychedelic Beacon (tracker)
Bonus: the wave of label updates
In these two weeks alone, the FDA moved more than ten approvals and indication expansions — each one a campaign trigger with budget typically already allocated:
- Sanofi — expanded use in type 1 diabetes
- Lilly EBGLYSS (lebrikizumab) — every-8-weeks maintenance dosing in atopic dermatitis
- Pfizer HYMPAVZI — two additional populations in hemophilia A and B
- Biogen LEQEMBI IQLIK — subcutaneous injection as initiation dosing in early Alzheimer's
- Casgevy (exa-cel) — gene therapy expanded to younger children
- Zoryve — expansion to children with plaque psoriasis
- Keytruda + Padcev — perioperative expansion in muscle-invasive bladder cancer
- Ryaltris — approval for children aged 6 to 11 with seasonal allergic rhinitis
- Risankizumab — approval affecting pediatric psoriasis and psoriatic arthritis
- Tocilizumab biosimilar — label expanded for CRS and pediatric COVID-19
The operational reading: the competitive edge is not in knowing the approval came through — it is in how fast you turn it into approved, live creative. Teams that depend on manual workflows miss the window.
About this radar
This report covers July 9 to 23, 2026 and was built from automated monitoring of the US trade press, with editorial curation and analysis. Primary sources include MM+M, Fierce Pharma, PharmaVoice, Pharmaceutical Executive, BioPharma Dive, Reuters, STAT News, CNBC, Bloomberg, Forbes, Campaign US, MediaPost, PulsePoint, DeepIntent, Innovid, CMS.gov, and the Federal Register. All links are listed at the end of each section.
Brands-TI works in technical production and digital project management for the healthcare and pharmaceutical sector, specializing in Veeva CRM, Veeva Vault (PromoMats and Approved Email), Salesforce, and marketing workflow automation. If any of the moves above touches your brand's operation, talk to us.
Published at brands-ti.com.br. Reproduction permitted with attribution and a link to the original source.